NCT02989727View on ClinicalTrials.gov

Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

August 31, 2005

Study Completion Date

December 31, 2017

Conditions
DepressionBipolar DisorderBipolar DepressionMelancholiaLamotrigine
Interventions
DRUG

Lamotrigine

Lamotrigine tablets at dosages of 25mg/day for Week 1 and Week 2, 50mg/day for Week 3 and Week 4, 100mg/day for Week 5, and 200mg/day for Week 6, Week 7, and Week 8.

DRUG

Placebos

Placebo tablets

Trial Locations (1)

S7N0W8

Department of Psychiatry, Royal University Hospital, Saskatoon

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Saskatchewan

OTHER

NCT02989727 - Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine | Biotech Hunter | Biotech Hunter